Clinical Trial Update: Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov entry reports the completion of a Phase 2 study evaluating SANGUINATE for treatment of vaso-occlusive crisis in sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Sickle Cell Disease

Drugs mentioned

• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Anemia, Sickle Cell | Phase 2 | Status: COMPLETED